RxDoctor Payments Data

Michel Woodbury

Psychiatry · San Juan, PRNPI 1720099989

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,274 of the $6,339 with a category attached, or 83.2%. 11 manufacturers reported payments, led by AbbVie at 56.9% of the total. Among psychiatry clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,339in general payments, 2019–2025

Across 138 payments — averaging $45.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Tris Pharma Inc$1K
  • Johnson & Johnson$402
  • Otsuka America Pharmaceutical, Inc.$388
  • Teva Pharmaceuticals USA, Inc.$345
  • E.r. Squibb & Sons, L.L.C.$333
  • plus $263 from 5 others
$24,146in research payments, 2019–2025

Across 4 payments — averaging $6036.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$16K
  • Genentech, Inc.$8K

What the payments were for

  • Consulting fees$1,05017%
  • Travel & lodging$150%
  • Food & beverage$5,27483%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,339 in reported general payments places this provider in the 95th percentile of 312 psychiatry providers in Puerto Rico.

See all psychiatry providers in Puerto Rico

Most prescribed under Part D

DrugClaimsCost to plans & patients
DepakoteDivalproex Sodium13$5,571
AmantadineAmantadine Hcl69$4,582
Potassium Chloride64$4,377
Chlorpromazine Hcl21$4,131
Fluvoxamine Maleate88$3,970
Liothyronine Sodium57$3,415
Bromocriptine Mesylate23$2,936
Clonazepam180$2,682
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine37$2,027
SynthroidLevothyroxine Sodium33$1,923
Bupropion Hcl SrBupropion Hcl81$1,723
Aripiprazole35$1,437
Divalproex Sodium17$1,414
Hydroxychloroquine Sulfate17$1,368
Fenofibrate43$1,342

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$3,608$1,92333 claims
Lilly USA, LLCOlanzapine$91$96135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 312 psychiatry providers in Puerto Rico.

Other psychiatry in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →